The objectives of this contract are: 1) when testing new agents which have just completed Phase I trials, to confirm that the dose and schedule chosen can be safely given in subsequent Phase II trials; 2) to determine the antitumor activity of existing antitumor agents which can be administered in significantly higher doses when used with colony stimulating factors or other factors which modulate toxicity or antitumor activity; 3) to determine the antitumor activity of combinations of antitumor agents and modalities; 4) to evaluate the laboratory parameters which may correlate with or predict for response; and 5) to determine the spectrum or antitumor activity for new agents in selected human cancers. While the contract will permit occasional Phase III trials, the major emphasis shall be on the early Phase II studies which are pivotal for drug development and require rapid initiation, completion and data reporting.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM007311-010
Application #
3607942
Study Section
Project Start
1990-05-01
Project End
1996-11-30
Budget Start
1993-09-09
Budget End
1993-11-30
Support Year
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Memorial Hospital for Cancer & Allied Di
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10021
Ajani, J A (1997) Treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 24:S19-72-S19-76
Ajani, J A; Ilson, D H; Kelsen, D P (1996) Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 23:55-8
Ajani, J A; Ilson, D H; Kelsen, D P (1995) The activity of paclitaxel in gastrointestinal tumors. Semin Oncol 22:46-50;discussion 51-3
Ajani, J A; Ilson, D H; Daugherty, K et al. (1995) Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol 22:35-40
Kelsen, D P; Saltz, L; Cohen, A M et al. (1994) A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer 74:2224-33
Pfister, D G; Bajorin, D; Motzer, R J et al. (1993) A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer. Invest New Drugs 11:53-6
Hudis, C A; Kelsen, D P (1992) Menogaril in the treatment of malignant mesothelioma: a phase II study. Invest New Drugs 10:103-6